Last reviewed · How we verify
repaglinide and metformin combination tablet
Repaglinide stimulates insulin secretion from the pancreas, while metformin decreases glucose production in the liver and increases insulin sensitivity.
Repaglinide stimulates insulin secretion from the pancreas, while metformin decreases glucose production in the liver and increases insulin sensitivity. Used for Type 2 diabetes.
At a glance
| Generic name | repaglinide and metformin combination tablet |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | DPP-4 inhibitor and biguanide |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Repaglinide works by closing potassium channels in the beta cells of the pancreas, leading to insulin release. Metformin, on the other hand, decreases glucose production in the liver by inhibiting gluconeogenesis and increases insulin sensitivity by reducing glucose uptake in the liver and increasing glucose uptake in muscles.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
- Headache
- Dizziness
Key clinical trials
- A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (PHASE4)
- Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir (PHASE1)
- Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (PHASE4)
- Metformin in Patients With Fragile X (PHASE1, PHASE2)
- A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313) (PHASE4)
- Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers (PHASE1)
- Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes (PHASE3)
- Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: